1 Type of the Paper (Article)

2

A retrospective case-control study for Clinical Validation of mutated ZNF208 as a novel biomarker of fatal blast crisis in Chronic Myeloid Leukemia

- 6 Nawaf Alanazi¹, Abdulaziz Siyal², Salman Basit³, Masood Shammas⁴, , Aamer Aleem², Amer Mahmood², Sarah
- 7

Al-Mukhaylid^{5,6} and Zafar Iqbal^{5,6,7,8,9}

- ⁸ ¹Department of Pediatrics, King Abdulaziz Hospital, Al-Ahsa, Saudi Arabia.
- ⁹ ²College of Medicine, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia.
- ¹⁰ ³Centre for Genetics and Inherited Diseases, Taiba University, Madinah, Saudi Arabia.
- ⁴Dana Farbar Cancer Institute, University of Harvard, Boston USA.
- ¹² ⁵Clinical Laboratory Sciences Program (CLAB), COAMS-A, King Saud Bin Abdulaziz University for Health Sciences/KAIMRC:
- 13 King Abdulaziz Medical City, Al Ahsa, Saudi Arabia.
- ¹⁴ ⁶Genomic Medicine & Oncology/Hematology Group, CoAMS-A, King Saud Bin Abdulaziz University for Health Sciences & King
- 15 Abdullah International Medical Research Centre (KAIMRC) / SSBMT, King Abdulaziz Medical City, National Guard Health
- 16 Affairs, Al-Ahsa, Saudi Arabia.
- ¹⁷ ⁷Hematology, Oncology & Pharmacogenetic Engineering Sciences (HOPES) Group, Department of Zoology, Univ. of Punjab,
- 18 Pakistan (King Saud Bin Abdulaziz Univ.), Lahore, Pakistan.
- ¹⁹ ⁸Pakistan Society for Molecular and Clinical Hematology, Lahore, Pakistan.
- ²⁰ ⁹Centre for Applied Molecular Biology (CAMB), University of the Punjab, Lahore 54590, Pakistan.
- 21 *Corresponding authors
- 22 Dr. Amer Mahmood and Dr. Zafar Iqbal
- 23 <u>ammahmood@ksu.edu.sa</u>, <u>Drzafar.medgen1@gmail.com</u>; <u>iqbalz@ksau-hs.edu.sa</u>
- 24
- 25 Article Type: Research Article

26

- ,
- 27 28
- 29
- 30
- 31

Simple Summary: Chronic Myeloid Leukemia (CML) is a type of blood cancer caused by the 32 BCR-ABL1 fusion oncogene, leading to genetic instability and other genetic changes. This results 33 in advancement from a manageable Chronic Phase (CP) to an accelerated phase (AP) and finally a 34 lethal blast crisis phase (BC). The mechanism of CML development is not well known, and there is 35 36 a dearth of dependable shared molecular indicators. Transcription factors (TFs) are a class of molecules that, when altered, significantly contribute to the development and advancement of 37 38 cancer, including relapses, invasion, metastasis, and resistance to anti-cancer drugs. Recently, ZNF208 was has been reported to be novel transcription factor gene associated with BC-CML. 39 Here, we carried out clinical validation of ZNF208 as a novel biomarker of CML progression us-40 ing targeted resequencing. ZNF208 mutation (c.64G>A) was detected in 0 (0%), 56 (93.3) and 12 41 (100) CP-, AP- and BC-CML patients respectively (p=0.0001) demonstrating its very high speci-42 ficity for AP- and BC-CML. This shows that ZNF208 mutation (c.64G>A) is a very specific bi-43 omarker for CML progression. We recommend prospective clinical trials for further clinical vali-44 dation of this novel biomarker for CML progression. 45

46 Abstract:

The hallmark of Chronic Myeloid Leukemia (CML) is Philadelphia chromosome t(9:22), which 47 leads to formation of BCR-ABL1 fusion oncogene. BCR-ABL1 induces genetic instability, causing 48 the progression of chronic myeloid leukemia (CML) from the manageable Chronic Phase 49 50 (CP-CML) to the accelerated phase (AP-CML) and ultimately to the lethal blast crisis (BC-CML). The precise mechanism responsible for CML progression are not well comprehended, and there is 51 a lack of specific molecular biomarkers for advanced phase CML. Mutations in transcription fac-52 tors (TFs) have a significant role in cancer initiation, relapses, invasion, metastasis, and resistance 53 to anti-cancer drugs. Recently, our group reported association of a novel transcription factor, 54 ZNF208, with CML progression and there was a dire need for clinical validation of this novel 55 biomarker. Therefore, the aim of this study was to clinically validate mutated ZNF208 as a novel 56 biomarker for CML progression in a larger cohort of AP- and BC-CML patients using control-case 57 studies. 58

- A total of 73 CML patients (N=73) from King Saud University Medical City Riyadh and King 59 Abdulaziz National Guard Hospital, Al-Ahsa, Saudi Arabia were enrolled in the study 60 (2020-2023), with the experimental group (cases) consisting of patients AP-CML (n=20) and 61 BC-CML (n=12). The controls consisted of age/sex matched CP-CML (n=41). The study was ap-62 proved by Research Ethics Committees of participating institutes and all patients provided in-63 formed consent for the study. Clinical evaluations for patients were conducted according to the 64 guidelines established by the European LeukemiaNet in 2020. Targeted resequencing of ZNF 208 65 was employed using Illumina NextSeq500 instrument (Illumina, San Diego, CA, USA) and muta-66 tions confirmed using Sanger sequencing. 67
- Both next generation sequencing as well as Sanger sequencing identified a novel missense muta-68 tion (c.64G>A) in novel ZNF208. in 56 (93.3) and 12 (100) CP-, AP- and BC-CML patients respec-69 tively, while in none (0%) of CP-CML patients or healthy controls from genomic databases 70 (p=0.0001). Therefore, our studies show that ZNF208 mutation (c.64G>A) is novel and very spe-71 cific biomarker for AP-and BC-CML patients. ZNF208 and other such proteins may cause car-72 73 cinogenesis by interacting with KAP-1 repressor to silence many target genes and thus may prove 74 to be novel drug targets as well. Therefore, we recommend carrying out prospective clinical trials 75 for further clinical validation of this biomarker for its utilization in clinical decision, investigating

- its precise role in cancer pathogenesis and investigate its potential for novel drug target in ad vanced phase CML patients.
- Keywords: Chronic Myeloid Leukemia; Blast crisis; Disease Progression Mechanism; Molecular
 Biomarkers; Transcription Factors; Zing Finger Proteins; Cancer.
- 80

1. Introduction

81

0.0	
82	Chronic myeloid leukemia (CML) is a type of blood cancer that affects the stem cells
83	responsible for producing blood cells. It is characterized by the excessive generation of
84	non-functional granulocytes in the bone marrow [1]. CML is characterized by the exist-
85	ence of the Philadelphia chromosome t(9:22), which is a reciprocal translocation between
86	the Abelson murine leukemia (ABL) gene on chromosome 9 and the breakpoint cluster
87	region (BCR) gene on chromosome 22 [2]. The fusion leads to the constant expression of
88	tyrosine kinase BCR-ABL on hematopoietic stem cells (HSCs), causing them to convert
89	into leukemic stem cells (LSCs) and facilitating uncontrolled development and replica-
90	tion [3]. An inherent characteristic of chronic myeloid leukemia (CML) is the presence of
	genomic instability induced by BCR-ABL itself. This instability results in the emergence
91	
92	of more mutations in both BCR-ABL and other genes as the disease advances [4].
93	
94	The milestone discovery of BCR-ABL tyrosine kinase inhibitors (TKIs), specifically
95	imatinib, has been a significant advancement in the treatment of chronic myeloid leu-
96	kemia (CML), making overall survival of CML patients equaling general public, at least
97	in technologically advanced countries [1]. This breakthrough has resulted in reduction in
98	the rate of progression of CML patients from the chronic phase to an accelerated phase
99	(AP-CML) and ultimately to a fatal blast crisis (BC-CML) [5]. Regrettably, certain indi-
100	viduals experience resistance to TKIs, resulting in therapy failure and progression to
101	BC-CML [6]. However, the exact mechanisms responsible for the progression of CML are
102	not fully understood, and there is a scarcity of reliable molecular markers for progression
103	of CML to accelerated and blast crisis phases [3]. It makes early detection of CML patients
104	at risk of disease progression, specifically to blast crisis, as one of biggest issues in 21st
105	century cancer medicine [5, 6].
105	
100	Transcription factors (TFs) have been found to be responsible for initiation onset,
106	Indiscription factors (IFS) have been found to be responsible for initiation onset.
107	invasion, drug-resistance, metastasis and progression, and hence morbidities and
107 108	invasion, drug-resistance, metastasis and progression, and hence morbidities and mortalty of a many types of cancers [7].Transcription factors (TFs) are proteins that se-
107 108 109	invasion, drug-resistance, metastasis and progression, and hence morbidities and mortalty of a many types of cancers [7].Transcription factors (TFs) are proteins that se- lectively attach to particular DNA sequences, facilitating the transfer of genetic infor-
107 108	invasion, drug-resistance, metastasis and progression, and hence morbidities and mortalty of a many types of cancers [7].Transcription factors (TFs) are proteins that se- lectively attach to particular DNA sequences, facilitating the transfer of genetic infor- mation from DNA to messenger RNA (mRNA) and thus function as regulators of gene
107 108 109	invasion, drug-resistance, metastasis and progression, and hence morbidities and mortalty of a many types of cancers [7].Transcription factors (TFs) are proteins that se- lectively attach to particular DNA sequences, facilitating the transfer of genetic infor- mation from DNA to messenger RNA (mRNA) and thus function as regulators of gene expression [8]. The activity of transcription factors (TFs) can be modified in cancer
107 108 109 110	invasion, drug-resistance, metastasis and progression, and hence morbidities and mortalty of a many types of cancers [7].Transcription factors (TFs) are proteins that se- lectively attach to particular DNA sequences, facilitating the transfer of genetic infor- mation from DNA to messenger RNA (mRNA) and thus function as regulators of gene expression [8]. The activity of transcription factors (TFs) can be modified in cancer through many direct and indirect mechanisms including chromosomal translocations,
107 108 109 110 111	invasion, drug-resistance, metastasis and progression, and hence morbidities and mortalty of a many types of cancers [7].Transcription factors (TFs) are proteins that se- lectively attach to particular DNA sequences, facilitating the transfer of genetic infor- mation from DNA to messenger RNA (mRNA) and thus function as regulators of gene expression [8]. The activity of transcription factors (TFs) can be modified in cancer
107 108 109 110 111 112	invasion, drug-resistance, metastasis and progression, and hence morbidities and mortalty of a many types of cancers [7].Transcription factors (TFs) are proteins that se- lectively attach to particular DNA sequences, facilitating the transfer of genetic infor- mation from DNA to messenger RNA (mRNA) and thus function as regulators of gene expression [8]. The activity of transcription factors (TFs) can be modified in cancer through many direct and indirect mechanisms including chromosomal translocations,
107 108 109 110 111 112 113	invasion, drug-resistance, metastasis and progression, and hence morbidities and mortalty of a many types of cancers [7].Transcription factors (TFs) are proteins that se- lectively attach to particular DNA sequences, facilitating the transfer of genetic infor- mation from DNA to messenger RNA (mRNA) and thus function as regulators of gene expression [8]. The activity of transcription factors (TFs) can be modified in cancer through many direct and indirect mechanisms including chromosomal translocations, gene amplification, deletion, point mutations, altered gene expression, noncoding RNAs,
107 108 109 110 111 112 113 114	invasion, drug-resistance, metastasis and progression, and hence morbidities and mortalty of a many types of cancers [7].Transcription factors (TFs) are proteins that se- lectively attach to particular DNA sequences, facilitating the transfer of genetic infor- mation from DNA to messenger RNA (mRNA) and thus function as regulators of gene expression [8]. The activity of transcription factors (TFs) can be modified in cancer through many direct and indirect mechanisms including chromosomal translocations, gene amplification, deletion, point mutations, altered gene expression, noncoding RNAs, DNA methylation and histone structure through epigenetic factors [9]. Although TFs are
107 108 109 110 111 112 113 114 115	invasion, drug-resistance, metastasis and progression, and hence morbidities and mortalty of a many types of cancers [7].Transcription factors (TFs) are proteins that se- lectively attach to particular DNA sequences, facilitating the transfer of genetic infor- mation from DNA to messenger RNA (mRNA) and thus function as regulators of gene expression [8]. The activity of transcription factors (TFs) can be modified in cancer through many direct and indirect mechanisms including chromosomal translocations, gene amplification, deletion, point mutations, altered gene expression, noncoding RNAs, DNA methylation and histone structure through epigenetic factors [9]. Although TFs are recognized to have a significant role in the development of acute leukemias, their specific
107 108 109 110 111 112 113 114 115	invasion, drug-resistance, metastasis and progression, and hence morbidities and mortalty of a many types of cancers [7].Transcription factors (TFs) are proteins that se- lectively attach to particular DNA sequences, facilitating the transfer of genetic infor- mation from DNA to messenger RNA (mRNA) and thus function as regulators of gene expression [8]. The activity of transcription factors (TFs) can be modified in cancer through many direct and indirect mechanisms including chromosomal translocations, gene amplification, deletion, point mutations, altered gene expression, noncoding RNAs, DNA methylation and histone structure through epigenetic factors [9]. Although TFs are recognized to have a significant role in the development of acute leukemias, their specific
107 108 109 110 111 112 113 114 115 116	invasion, drug-resistance, metastasis and progression, and hence morbidities and mortalty of a many types of cancers [7].Transcription factors (TFs) are proteins that se- lectively attach to particular DNA sequences, facilitating the transfer of genetic infor- mation from DNA to messenger RNA (mRNA) and thus function as regulators of gene expression [8]. The activity of transcription factors (TFs) can be modified in cancer through many direct and indirect mechanisms including chromosomal translocations, gene amplification, deletion, point mutations, altered gene expression, noncoding RNAs, DNA methylation and histone structure through epigenetic factors [9]. Although TFs are recognized to have a significant role in the development of acute leukemias, their specific contribution to the progression of CML is still largely understood.
107 108 109 110 111 112 113 114 115 116	invasion, drug-resistance, metastasis and progression, and hence morbidities and mortalty of a many types of cancers [7].Transcription factors (TFs) are proteins that se- lectively attach to particular DNA sequences, facilitating the transfer of genetic infor- mation from DNA to messenger RNA (mRNA) and thus function as regulators of gene expression [8]. The activity of transcription factors (TFs) can be modified in cancer through many direct and indirect mechanisms including chromosomal translocations, gene amplification, deletion, point mutations, altered gene expression, noncoding RNAs, DNA methylation and histone structure through epigenetic factors [9]. Although TFs are recognized to have a significant role in the development of acute leukemias, their specific contribution to the progression of CML is still largely understood. Our laboratory recently showed a novel transcription factor ZNF208 with a missense mutation (c.64G>A) associated with the progression of chronic myeloid leukemia (CML)
107 108 109 110 111 112 113 114 115 116 117 118 119	invasion, drug-resistance, metastasis and progression, and hence morbidities and mortalty of a many types of cancers [7].Transcription factors (TFs) are proteins that se- lectively attach to particular DNA sequences, facilitating the transfer of genetic infor- mation from DNA to messenger RNA (mRNA) and thus function as regulators of gene expression [8]. The activity of transcription factors (TFs) can be modified in cancer through many direct and indirect mechanisms including chromosomal translocations, gene amplification, deletion, point mutations, altered gene expression, noncoding RNAs, DNA methylation and histone structure through epigenetic factors [9]. Although TFs are recognized to have a significant role in the development of acute leukemias, their specific contribution to the progression of CML is still largely understood. Our laboratory recently showed a novel transcription factor ZNF208 with a missense mutation (c.64G>A) associated with the progression of chronic myeloid leukemia (CML) [10]. Keeping in view that no reliable molecular biomarker is currently in clinical practice
107 108 109 110 111 112 113 114 115 116 117 118 119 120	invasion, drug-resistance, metastasis and progression, and hence morbidities and mortalty of a many types of cancers [7].Transcription factors (TFs) are proteins that se- lectively attach to particular DNA sequences, facilitating the transfer of genetic infor- mation from DNA to messenger RNA (mRNA) and thus function as regulators of gene expression [8]. The activity of transcription factors (TFs) can be modified in cancer through many direct and indirect mechanisms including chromosomal translocations, gene amplification, deletion, point mutations, altered gene expression, noncoding RNAs, DNA methylation and histone structure through epigenetic factors [9]. Although TFs are recognized to have a significant role in the development of acute leukemias, their specific contribution to the progression of CML is still largely understood. Our laboratory recently showed a novel transcription factor ZNF208 with a missense mutation (c.64G>A) associated with the progression of chronic myeloid leukemia (CML) [10]. Keeping in view that no reliable molecular biomarker is currently in clinical practice to early detect the CML patients at risk of developing fatal blast crisis and their timely
107 108 109 110 111 112 113 114 115 116 117 118 119 120 121	invasion, drug-resistance, metastasis and progression, and hence morbidities and mortalty of a many types of cancers [7].Transcription factors (TFs) are proteins that se- lectively attach to particular DNA sequences, facilitating the transfer of genetic infor- mation from DNA to messenger RNA (mRNA) and thus function as regulators of gene expression [8]. The activity of transcription factors (TFs) can be modified in cancer through many direct and indirect mechanisms including chromosomal translocations, gene amplification, deletion, point mutations, altered gene expression, noncoding RNAs, DNA methylation and histone structure through epigenetic factors [9]. Although TFs are recognized to have a significant role in the development of acute leukemias, their specific contribution to the progression of CML is still largely understood. Our laboratory recently showed a novel transcription factor ZNF208 with a missense mutation (c.64G>A) associated with the progression of chronic myeloid leukemia (CML) [10]. Keeping in view that no reliable molecular biomarker is currently in clinical practice to early detect the CML patients at risk of developing fatal blast crisis and their timely therapeutic intervention in order to stop or delay their acute transformation [3, 5, 6],
107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122	invasion, drug-resistance, metastasis and progression, and hence morbidities and mortalty of a many types of cancers [7].Transcription factors (TFs) are proteins that se- lectively attach to particular DNA sequences, facilitating the transfer of genetic infor- mation from DNA to messenger RNA (mRNA) and thus function as regulators of gene expression [8]. The activity of transcription factors (TFs) can be modified in cancer through many direct and indirect mechanisms including chromosomal translocations, gene amplification, deletion, point mutations, altered gene expression, noncoding RNAs, DNA methylation and histone structure through epigenetic factors [9]. Although TFs are recognized to have a significant role in the development of acute leukemias, their specific contribution to the progression of CML is still largely understood. Our laboratory recently showed a novel transcription factor ZNF208 with a missense mutation (c.64G>A) associated with the progression of chronic myeloid leukemia (CML) [10]. Keeping in view that no reliable molecular biomarker is currently in clinical practice to early detect the CML patients at risk of developing fatal blast crisis and their timely therapeutic intervention in order to stop or delay their acute transformation [3, 5, 6] , there was an urgent need to clinically validate this important finding in a broader popu-
107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123	invasion, drug-resistance, metastasis and progression, and hence morbidities and mortalty of a many types of cancers [7].Transcription factors (TFs) are proteins that se- lectively attach to particular DNA sequences, facilitating the transfer of genetic infor- mation from DNA to messenger RNA (mRNA) and thus function as regulators of gene expression [8]. The activity of transcription factors (TFs) can be modified in cancer through many direct and indirect mechanisms including chromosomal translocations, gene amplification, deletion, point mutations, altered gene expression, noncoding RNAs, DNA methylation and histone structure through epigenetic factors [9]. Although TFs are recognized to have a significant role in the development of acute leukemias, their specific contribution to the progression of CML is still largely understood.
107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124	invasion, drug-resistance, metastasis and progression, and hence morbidities and mortalty of a many types of cancers [7].Transcription factors (TFs) are proteins that selectively attach to particular DNA sequences, facilitating the transfer of genetic information from DNA to messenger RNA (mRNA) and thus function as regulators of gene expression [8]. The activity of transcription factors (TFs) can be modified in cancer through many direct and indirect mechanisms including chromosomal translocations, gene amplification, deletion, point mutations, altered gene expression, noncoding RNAs, DNA methylation and histone structure through epigenetic factors [9]. Although TFs are recognized to have a significant role in the development of acute leukemias, their specific contribution to the progression of CML is still largely understood.
107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123	invasion, drug-resistance, metastasis and progression, and hence morbidities and mortalty of a many types of cancers [7].Transcription factors (TFs) are proteins that se- lectively attach to particular DNA sequences, facilitating the transfer of genetic infor- mation from DNA to messenger RNA (mRNA) and thus function as regulators of gene expression [8]. The activity of transcription factors (TFs) can be modified in cancer through many direct and indirect mechanisms including chromosomal translocations, gene amplification, deletion, point mutations, altered gene expression, noncoding RNAs, DNA methylation and histone structure through epigenetic factors [9]. Although TFs are recognized to have a significant role in the development of acute leukemias, their specific contribution to the progression of CML is still largely understood.
107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125	invasion, drug-resistance, metastasis and progression, and hence morbidities and mortalty of a many types of cancers [7].Transcription factors (TFs) are proteins that selectively attach to particular DNA sequences, facilitating the transfer of genetic information from DNA to messenger RNA (mRNA) and thus function as regulators of gene expression [8]. The activity of transcription factors (TFs) can be modified in cancer through many direct and indirect mechanisms including chromosomal translocations, gene amplification, deletion, point mutations, altered gene expression, noncoding RNAs, DNA methylation and histone structure through epigenetic factors [9]. Although TFs are recognized to have a significant role in the development of acute leukemias, their specific contribution to the progression of CML is still largely understood.
107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124	invasion, drug-resistance, metastasis and progression, and hence morbidities and mortalty of a many types of cancers [7].Transcription factors (TFs) are proteins that selectively attach to particular DNA sequences, facilitating the transfer of genetic information from DNA to messenger RNA (mRNA) and thus function as regulators of gene expression [8]. The activity of transcription factors (TFs) can be modified in cancer through many direct and indirect mechanisms including chromosomal translocations, gene amplification, deletion, point mutations, altered gene expression, noncoding RNAs, DNA methylation and histone structure through epigenetic factors [9]. Although TFs are recognized to have a significant role in the development of acute leukemias, their specific contribution to the progression of CML is still largely understood.
107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125	invasion, drug-resistance, metastasis and progression, and hence morbidities and mortalty of a many types of cancers [7].Transcription factors (TFs) are proteins that selectively attach to particular DNA sequences, facilitating the transfer of genetic information from DNA to messenger RNA (mRNA) and thus function as regulators of gene expression [8]. The activity of transcription factors (TFs) can be modified in cancer through many direct and indirect mechanisms including chromosomal translocations, gene amplification, deletion, point mutations, altered gene expression, noncoding RNAs, DNA methylation and histone structure through epigenetic factors [9]. Although TFs are recognized to have a significant role in the development of acute leukemias, their specific contribution to the progression of CML is still largely understood.

128

2. Materials and Methods

129 130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145 146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174 175

176 177 This study focused on recruiting and selecting patients with Chronic Myeloid Leukemia (CML) who were enrolled at King Saud University Medical City Riyadh and King Abdulaziz National Guard Hospital Al-Ahsa in Saudi Arabia (N=73). The study period spanned from January 2020 to July 2023. The study comprised a total of 41 patients diagnosed with chronic phase chronic myeloid leukemia (CP-CML) as control group. The experimental group consisted of 20 patients with Accelerated Phase (AP-CML) and 12 patients with Blast crisis CML (BC-CML). Initially, all CP-CML patients received imatinib mesylate (IM) as their first-line treatment. Patients who did not respond well to IM were subsequently administered 2nd and third line tyrosine kinase inhibitors (TKIs)[12].

The criteria for treatment responses were adopted from the European LeukemiaNet (ELN) recommendations 2020 [11]. The definitions of clinical stages of chronic myeloid leukemia were adopted as in previous ELN guidelines [12, 13]. Nevertheless, the presence of resistance to two tyrosine kinase inhibitors (TKIs), identification of a mutation in the kinase domain (KD) of the BCR-ABL1 gene, or the development of other chromosome abnormalities in Philadelphia chromosome positive (Ph+) cells (ACA) give rise to worries over the advancement of the disease [11]. Evaluation standards for measuring the effectiveness of treatment in individuals with chronic myeloid leukemia related to hematological responses and cytogenetic responses were based on previous ELN guidelines [12, 13] and studies carried out previously [14-16]. Nevertheless, molecular response definitions were adopted from ELN 2020 guidelines [12].

Overall survival referred to the duration of time from the initiation of IM treatment to either the date of the patient's death or the most recent follow-up [17]. Progression-free survival (PFS) was evaluated from the initiation of IM treatment until the development of chronic myeloid leukemia (CML) into accelerated phase (AP) or blast crisis (BC), or until death occurred. On the last follow-up date, every patient who had experienced a sustained event up until the last day of the study was excluded from the data. The survival status of patients who were not present during the previous follow-up was confirmed by reaching out to them using their recorded personal information. The Kaplan-Meier Method was selected for the purpose of conducting survival analysis [18]. Standard terminologies (version 4.03) were used for the classification of hemolytic adverse effects [12, 19].

All procedures used in this investigation were approved King Abdullah International Medical Research Center (KAIMRC) and King Saud University Medical City, Riyadh, Saudi Arabia and ethical approval from these centres was obtained per their regulatuions. Each patient who was enrolled in the trial provided signed informed consent to take part. All of the Declaration of Helsinki's codes were followed by the consent form [20].

Ten milliliters of peripheral blood were drawn for this investigation and placed in EDTA tubes. (BD Vacutainer Systems, located in Franklin Lakes, New Jersey.) The QIAamp DNA Blood Mini Kit (QIAGEN) was utilized for DNA extraction, and the NanoDrop Spectrophotometer (NanoDrop Technologies, Inc., USA) was employed for DNA quantification. After dilution, aliquots of 70–80 ng/ μ l were created in order to detect mutations using Whole Exome Sequencing (WES). To perform Sanger Sequencing, the residual DNA has to be diluted to 40 ng/ μ l. The DNA samples were kept in a refrigerator at -80°C [21-22].

Next Generation Sequencing (NGS) was used to do targeted resequencing of the ZNF208 gene.

In order to depict each stage of the disease (Chronic Phase and Accelerated Phase), carefully selected and thoroughly analyzed samples of CML were utilized for NGS. The Illumina® DNA Prep with Enrichment, (S) Augmentation kit (Cat. # 20025523) was used to enrich the target DNA for ZNF208 [22, 23]. The initial stage of Next-Generation Sequencing (NGS) involved the process of DNA fragmentation, which was then followed by tagmentation. Subsequently, the DNA fragments that had been tagged were amplified and subsequently purified using magnetic beads. Subsequently, Oligos were employed to capture specific regions of interest. The amplified libraries were enriched using PCR and their quantity was determined using a Qubit fluorometer. The library size distribution was measured using an Agilent Bioanalyzer. The Illumina NextSeq500 instrument was used to perform cluster generation and exon sequencing. The quantified DNA libraries were loaded onto the flow cell for this purpose [22, 23].

193 Analysis of Next Generation Sequencing (NGS) Data

The BCL2FASTQ software was used to convert the output files, specifically the BCL files, into FASTQ files. The BWA Aligner was used to align the FASTQ data to the human genome, utilizing the BWA-MEM algorithm. The Genome analysis tool kit (GATK) was used to identify variants. The genomic variations were annotated and filtered using Illumina Variant Studio [22,24].

Primary Analysis: The ZNF208 gene was examined in all patients with AP-CML to identify common biomarkers associated with the progression of chronic myeloid leukemia (CML). Filtering techniques that utilized the identification of uncommon genetic variations and the exclusion of intron and synonymous variations were employed to change the excel file that presents Next-Generation Sequencing (NGS) data. In addition, any variations that had a known prediction of being either benign (B) or tolerant (T) were eliminated. According to Carson (2014), certain variations were labeled as B if they had a frequency of 70% or higher for B, while other variants were categorized as T if their frequency for T was 70% or higher [25]. Any variants with a population frequency greater than 0.005 in the dbSNP and Exome Sequencing Project (ESP) database were also excluded. Therefore, the process of identifying variants was restricted to only those with significant protein impacts and splice variants. In addition, the data was subjected to additional analysis in order to examine new genetic variants that are found in patients with advanced phase chronic myeloid leukemia (AP-CML & BC-CML), but not in patients with chronic phase chronic myeloid leukemia (CP-CML) or healthy individuals. This suggests that these mutations may have a role in the progression of the disease [26, 27]. The data generated by next-generation sequencing can be accessible from the National Center for Biotechnology Information (NCBI), where it was submitted.

218

178

179

180

181

182

183

184 185

186

187

188

189

190

191

192

194

195

196

197

198

199

200

201

202 203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

219

220

221

222

223

224

225

Sanger sequencing to validate mutations.

Sanger sequencing was used to verify the variations identified by WGS. The University of California Santa Cruz's genome database browser was used to retrieve the genomic primers for the variations found in the indicated genes (Table 2); primers themselves were from Applied Biosystems in California, USA. The process of amplifying Template DNA involved PCR. DNA sequencing reactions were performed using ABI PRISM Big Dye Terminator Cycle Sequencing Ready Reaction kits (Applied Biosystems, California, USA) [28]. The ABI Prism 3730 Genetic Analyzer (Applied

226 227				fornia, USA) (http://genome.ucsc.edu/cgil sequencing on both forward and reverse I		
228	Analysis of patient clinical data using statistical methods.					
229		The normalc	y te	st provided evidence for percentages, abs	olute nu	umbers, and categor-
230				ntinuous data, the same procedure was us		
231		measure of v	aria	ance. We used Fisher's exact test or Chi-	Square †	test to compare two
232		means of cate	egoi	rical data. The Mann-Whitney U test or a t	wo-samp	ple independent test
233		were utilized	l foi	r continuous data. Furthermore, ANOVA o	or Krusk	kal-Wallis tests were
234				certain the variance for groups of ≥3. The		
235				lan-Meier survival analysis curves [18]. '		
236				; the log-rank test. Version 9.4 of the SAS		
237				IC, USA) was used for data analysis. For s		
238				used (Vienna, Austria) [31]. The Sokal risl	c score, l	Eutos risk score, and
239 240		Euro risk sco	re w	vere calculated [11, 32–35].		
241						
242	Tal	ble 1. Common v	varia	nts in Accelerated/Blast Phase-Chronic Myeloid Leuk	cemia patie	ents (AP, n=5,
243		; n=7), primers d F208 genes.	lesig	ned to amplify the regions around the detected variar	nts in FAN	ICD2 and
244	#	Gene Sym-	Se	quence	Size	Tm
		bol		-	(bp)	
245	1	ZNF208-F	5`	TCTGCCCATGTCCAGTTGAT 3`	234	61.5°C
246	2	ZNF208-R	5`	GGTCTGCAGCAAAATGAAACC 3`	_	61.9°C
247		gend: F= forward ree centigrade	d pri	mer, R= reverse primer, bp= base pair, Tm= melting	temperatu	ıre, °C=
248						
249						
250						
251						
252						
253						
254						
255						
256						
257						
258						
259						

260	Results		
261		3.1 Demographics	
201			
262		A total of 73 patients with CML were enrolled in this study	. The mean age was 34.6
263		years, and the male-to-female ratio was 1.6.1, with 60% males an	
264		mean hemoglobin, WBC count, and platelets were 10.1, 317.9, and	
265		(Table 2). Overall, males were more commonly affected by CML	•
266			
267		Table 2. Demographics and Laboratory Parameters In Our Study	
268		Characteristics	# of Patients, %
269		$T_{otol}(n-72)$	
270		Total (n=73) Age, yrs	
271		Mean (range)	34.6
271		Gender	
272		Male	44 (63%)
273		Female	29(39.37%
		Ratio: Male: Female	1.6:1
274		Hemoglobin (g/dL), Mean	10.1
275		WBC count ($\times 10^9$ /L), Mean	313.7
276		Platelets ($\times 10^9/L$) (n =108), Mean	400.2
277		The mean age of CP-, AP-, and BC-CML patients was 33.5	35.6 and 38.1 years re-
278		spectively. Additionally, all CML phases were dominate	
279		male-to-female ratio was 1.6:1, 1.9:1 and 2:1, in CP-, AP- and B	
280		tively, with more trend in CML progression in male patients th	an female though differ-
281		ences were not statistically different (Table 3) . CP, AP and \ensuremath{B}	
282		statistically significant differences with respect to leukocyte cour	0
283		(p=0.04), splenomegaly of spleen size 5cm or more, hepatome	
284		(p=0.001) and survival (p=0.001). Nevertheless, as none of these	-
285 286		early prediction of CML progression decisively, molecular generative reported ZNF208 gene was carried out to find out the genetic b	
280 287		and for validation of mutated ZNF208 as new biomarker of CMI	1 0
200			
288 289		3.2 Clinical validation of ZNf208 by Targeted resequencing	
290		Targeted resequencing employed to validate ZNF208 as n	ovel biomarker of CMI
290 291		progression in cases (AP- and BC-CML patients) and cont	
292		detected ZNF208 64G>A) mutaions in 0%, 93.3% and 100% of	
293		patients respectively. The results were confirmed by Sanger se	
294		ZNF208 is a very useful marker of CML progression with specific	
295			
296			

297

298 Table 3: A comparison between CP- and AP-CML patients in this study in regard to their demographic and

299 laboratory characteristics.

Characteristics	Patient Groups (%				
	CP-CML		AP-CML	BC-CML	P value
Patients' number (%)	41 (56.2)		20 (27.4)	12 (16.4)	
(Range)Mean age	33.5 (range 7-69)) 35.6 (range=27-43)		38.1 (29–50)	p=0.92205
Gender					
Male	25 (60.1)		13 (65)	8 (66.7)	Overall p=0.70745
Female	16 (39.9)		7(35)	4 (33.3)	Overall p=0.70675
Female Ratio :Male	1.6:1		1.9:1	2:1	
(dL/g)Mean Hemoglobin	10.1				
<12g/dl	34 (82.9)		17 (85)	9 (75)	Overall p=0.1988
>12g/dl	7 (17.1)		3 (15)	3 (25)	Overall p=0.43545
(L/109×)Mean WBC count	313.7	313.7		325	Overall p=0.1988
<50	20 (48.8)	20 (48.8)		2 (16.7)	p=0.89185
>/=50	21 51.2)		17 (85)	10 (83.3)	p= 0.04
Platelets (× 109/L) Mean		400.2	1		

<450	25 (61)	13 (65)	10 (83.3)	p=0.4543	
>/=450	16 (39)	7 (35)	2 (16.7)	p=0.58755	
Imatinib					
Yes	41 (100)	13 (65)	0 (0)	p=0.05	
Chemotherapy					
Yes	0	0	8 (66.7)	P=0.0003	
Splenomegaly					
<5cm	2 (4.8)	0	0		
5-8cm	13 (31.7)	3 (15)	3 (25)	p=0.03	
>8cm	23 (56.1)	17 (85)	9 (75)	p=0.05	
No splenomegaly	3 (7.3)	(0) 0	0		
Hepatomegaly					
Yes	12 (29.3)	14 (70%)	8 (66.7)	p=0.006	
Survival Status					
Confirmed Deaths	0	1(5)	9 (75)	CP vs BC p < 0.0001	
Alive at last follow-up	41 (100)	19 (85)	3 (25)	CP vs BC p < 0.0001	
Patient positive for mutated ZNF208	0	56 (93.3)	12 (100)	CP vs BC p < 0.0001 CP vs AP P=0.0001	

300

301 302

303

304

305

The mutation detected in ZNF208 is new point mutation (c.64G>Ain which Guanine was replaced by Adenine at the at condon 22 at position 64 downstream of ZNF208 promoter. This change resulted in Asparagine instead of Aspartate at protein level.




Figure 2: Validation of missense mutation ZNF208 (c.64G>A) by Sanger sequencing.

Thus, it is concluded that ZNF208, a member of the zinc-finger binding transcription factor family, is mutated in all BC-CML and 93% AP-CML patients, with an impact on change in znf208 protein sequence, thus suggesting it to be a "likely to be pathogenic" mutation and a very important and novel molecular biomarker for CML progression that can help in early identification of patients at risk of ftransformation to fatal BC-CML and thus prividing the oncologists opprtunity to therapeutically intervence such high=risk CML patients using a varierty of newly developed BCR-ABL inhibitors The study shoul be furthr extended to unravel the role of ZNF208 in CML pathogenesis and prospective clinical trials should be carried out to further evaluate the role of ZNF208 G64A mutation and other such mutations of this important gene as a novel biomarker and primising drug target for AP- and BC-CML.

4. Discussion

333	This study included a total of 73 as case-control subjects that were from different phases of
334	chronic myeloid leukemia (CML). The case-control based clinical validation of potential disease
335	biomarker is a gold standard in discovery and clinical validation of novel biomarkers [36, 37]. We
336	used NGS-based targeted resequencing and Sanger sequencing for clinical validation of ZNF
337	G64A mutation as AP-/BC-CML. Targeted resequencing and Sanger sequencing along with other
338	similar techniques are routinely being used for clinical validation of molecular biomarkers [38-45].
339	Moreover, incorporation of next-generation sequencing, and other high-throughput techniques
340	have refined the discovery and validation of diagnostic and prognostic biomarkers and their in-
341	corporation into precision medicine [43-51].
342	
343	Our findings revealed that the ZNF208 gene remained unaltered in chronic phase CML patients as
344	well as in healthy individuals. However, it was shown to be mutated in all patients in the advanced
345	phase. The relationship between CML advancement and the development of a lethal blast crisis can
346	be attributed to ZNF208, a member of the biologically significant group of genes known as Zinc
347	Finger Proteins. The human genome contains a large number of zinc finger (ZNF) genes, with
348	around 500-600 members [50]. These proteins have a role in controlling genes and the process of
349	development, and they have remained mostly the same throughout evolution [51].
350	Research has indicated that the aberrant synthesis of many ZNF proteins [52] has an impact on
351	cancer development through several mechanisms. ZNF309 has been detected in various types of
352	cancer, including colorectal cancer, multiple myeloma, prostate cancer, cervical cancer, colon
353	cancer, ovarian cancer, and neuroblastoma [53]. An relationship was discovered between elevated
354	gene expression of ZNF-281 and many cancers including pancreatic, colon, breast, neuroblastoma,
355	and ovarian malignancies. The findings indicated that there was an overexpression of the ZNF-281
356	protein, which was connected with the development of the disease [53]. However, there was a
357	reduction in the expression of ZNF-281 observed in relation to the development of cancer. Spe-
358	cifically, while excessive expression of ZNF-281 may be associated with a negative prognosis, it
359	actually suppresses the development of cancer in glioma and non-small cell lung cancer, but in a
	contrasting manner [52]. ZNF proteins have recently been identified as protectors of genomic in-
360	tegrity. Mutations in ZNF genes can cause genomic instability through well-known mechanisms
361	[54].
362	[34].
363	
364	As previously mentioned, we identified a missense mutation in the ZNF208 gene that is specifically
365	linked to patients with advanced phase and blast crisis chronic myeloid leukemia (CML). This mutation results in the substitution of Aspartate with Asparagine in the ZNF208 protein. The
366	ZNF208 gene is situated on Chromosome 19 in the p12 region [55]. It interacts with DNA and
367	
368	regulates the process of gene transcription [50, 56]. Furthermore, additional research has demon-
369	strated a correlation between ZNF208 and various other medical conditions. A Genome-Wide
370	Association Study (GWAS) identified a correlation between telomere length and the ZNF208 gene
371	[57]. A study conducted in China indicates a correlation between Single nucleotide polymorphisms
372	(SNPs) in ZNF208 and susceptibility to Hepatitis B virus (HBV). The study included of 300
373	healthy volunteers and 242 patients who tested positive for HBV. The results suggest that ZNF208
374	variations may have a substantial impact on the progression of HBV. The study found that ZNF208
375	polymorphisms significantly increased susceptibility to HBV infection (P = 0.008) [50]. Fur-
376	thermore, a scientific investigation has asserted that mutations in the ZNF208 gene are associated
377	with an inclination towards developing esophageal cancer [58]. According to another study, the
378	likelihood of developing laryngeal cancer increases when there are particular variations in the
379	ZNF208 gene, specifically the rs8103163 A and rs7248488 A alleles [59]. A separate Chinese
380	study investigated the correlation between Chronic obstructive pulmonary disease (COPD) and

genetic variations in ZNF208. The study recruited 270 people with chronic obstructive pulmonary disease (COPD) and 288 individuals who were in good health. The study indicated that ZNF208 variations had an impact on telomere length in individuals with COPD [60]. Recently, it has been discovered that cirZNF208 has a function in the development of cervical cancer and has an impact on its prognosis. This demonstrates the significance of ZNF208 in the field of biology, particularly in relation to health and illness. It provides valuable insight into the vital function that ZNF208 plays in the progression of CML.

Mutations in the ZNF208 gene have the potential to serve as a new biomarker for tracking the progression of chronic myeloid leukemia (CML). Additionally, these mutations can aid in tailoring tailored treatment for patients with advanced phase CML and other types of cancer. ZNF 432 has recently been discovered to function as an effector of HR-based DNA repair. This finding suggests that PARylation may play a regulatory role in this mechanism [54]. PARYlation is known to coordinate the recruitment of crucial proteins involved in the DNA damage response and guide the DNA repair pathways. The expression of ZNF432 was reduced in cases of resistance to the PARP inhibitor Olaparib. Additionally, altering the expression of ZNF432 in ovarian cancer cells was observed to increase their susceptibility to PARP inhibitors such as Olaparib [54]. This study demonstrates that a growing collection of zinc finger proteins (ZFPs) have been discovered to affect the stability of the genome. These ZFPs have the potential to be used in the development of a predictive gene signature, which could have prognostic value in relation to ovarian cancer and its response to PARP inhibitors. The sources cited for this information are [54, 62, 63-66].

Some novel investigations have unraveled the mechanism of ZNF-mediated repression of transcription in genome. The proteins coded by ZNF genes have a Canonical Kruppel-associated box (KRAB) domain that has affinity for KRAB-associated protein-1 (KAP-1) or Trim28 [67]. KRAB-ZFP identifies a specific region in the genome that is intended for suppression. The engagement with dimeric Trim28 subsequently attracts the epigenetic apparatus to achieve strong transcriptional suppression [67-69]. As ZNF208 G64A mutation under our investigation also lies in KRAB domain of znf208 protein, it may have a role in KAP1-mediated repression of some other target proteins in the genome, leading to CML progression in our subset of CML patients and utilizing agonists of ZNFs and KP-1 can lead to development of novel anti-cancer drugs [69-70]. These studies show that by integrating multi-omics with artificial intelligence (AI), further studies can expedite the cancer drug development for treating the currently fatal phenotypes of cancers like blast-crisis CML [43-49.71].. Therefore, we recommend further investigations into role of mutated ZNF208 in CML progression, its validation as biomarker in prospective clinical trials and validating role of this and other such transcription factor as potential drug target in leukemia, cancers and other deadly diseases.

Therefore, it can be concluded that ZNF208, which is a member of the zinc-finger binding transcription factor family, is mutated in all patients with BC-CML and in 93% of patients with AP-CML. This mutation has an effect on the sequence of the ZNF208 protein, which suggests that it is a "likely to be pathogenic" mutation. Furthermore, it is a very important and novel molecular biomarker for the progression of CML. It can assist in the early identification of patients who are at risk of ftransformation to fatal BC-CML, thereby providing oncologists with the opportunity to therapeutically intervene in such high-risk CML patients by utilizing a variety of newly developed BCR-ABL inhibitors. In order to unravel the role that ZNF208 plays in the pathogenesis of chronic myelogenous leukemia (CML), the study should be further extended. Additionally, prospective clinical trials should be carried out in order to further evaluate the role of the ZNF208 G64A mutation and other similar mutations of this important gene as a novel biomarker and primary drug target for acute myelogenous leukemia (AP- and BC-CML).

431 5. Conclusions

432		We concluded that in our patient population, CML progression occurred at a high
433		rate. In advanced-phase CML patients, we discovered a novel transcription factor gene
434		associated with CML progression using next-generation sequencing, pointing to a shared
435		mechanism underlying CML's abrupt transformation. Future research is necessary to
436		confirm the functional genetic role of the gene in this study, and its evaluation as an early
437		biomarker of CML disease progression. This will undoubtedly be useful to utilize this
438		gene as a biomarker to determine subgroups of patients at risk of development of blast
439		crisis and to clinically intervene in acute CML transformation to halt disease progression.
440		To confirm our findings in a broader patient population and determine the precise func-
441		tion of this gene in the development of CML, more research is necessary. By using cut-
442		ting-edge cellular and molecular biological techniques, the potential of ZNF208 as a novel
443		therapeutic target for advanced-phase CML should also be investigated.
444		
445	Author Contributions:	
446		Conceptualization, Nawaf Alanazi and Zafar Iqbal; Data curation, Salman Basit, Formal analysis,
447		Zafar Iqbal; Investigation, Nawaf Alanazi, Salman Basit, and Zafar Iqbal; Methodology, Sarah
448		AlMukhaylid, i; Project administration, Zafar Iqbal; Resources, Nawaf Alanazi, Salman Basit and
449		Zafar Iqbal; Software, Salman Basit, Masood Shammad, Amer Mahmood, and Zafar Iqbal; Super-
450		vision, Zafar Iqbal; Validation, Amer Mahmood; Visualization, Sarah AlMukhaylid; Writing –
451		original draft, Aamer Aleem, , Sarah AlMukhaylid,; Writing – review & editing, Masood Shammad,
452		Aamer Aleem, , Sarah AlMukhaylid, and Zafar Iqbal.
453	Funding	
454	0	This project was funded by the National Plan for Science, Technology, and Innovation
455		(MAARIFAH), King Abdul-Aziz City for Science and Technology, Kingdom of Saudi Arabia, Grant
		Number 14-Med2817-02.
456		Number 14-medzo17-02.
457		
437		
458	Institutional Review Bo	pard Statement:
	Institutional Review Bo	bard Statement:
458 459	Institutional Review Bo	
458 459 460	Institutional Review Bo	The study was conducted in accordance with the Declaration of Helsinki, and was approved by
458 459 460 461	Institutional Review Bo	The study was conducted in accordance with the Declaration of Helsinki, and was approved by King Abdullah International Medical Research Centre (KAIMRC), National Guard Health Affairs,
458 459 460 461 462	Institutional Review Bo	The study was conducted in accordance with the Declaration of Helsinki, and was approved by King Abdullah International Medical Research Centre (KAIMRC), National Guard Health Affairs, Saudi Arabia, although no research funding was provided (project # RA17/002/A). This study was
458 459 460 461 462 463	Institutional Review Bo	The study was conducted in accordance with the Declaration of Helsinki, and was approved by King Abdullah International Medical Research Centre (KAIMRC), National Guard Health Affairs, Saudi Arabia, although no research funding was provided (project # RA17/002/A). This study was partially supported by the College of Medicine, Research Centre, Deanship of Scientific Research,
458 459 460 461 462 463 464	Institutional Review Bo	The study was conducted in accordance with the Declaration of Helsinki, and was approved by King Abdullah International Medical Research Centre (KAIMRC), National Guard Health Affairs, Saudi Arabia, although no research funding was provided (project # RA17/002/A). This study was partially supported by the College of Medicine, Research Centre, Deanship of Scientific Research, King Saud University, Riyadh, Saudi Arabia. All authors have read and have consented to the ac-
458 459 460 461 462 463	Institutional Review Bo	The study was conducted in accordance with the Declaration of Helsinki, and was approved by King Abdullah International Medical Research Centre (KAIMRC), National Guard Health Affairs, Saudi Arabia, although no research funding was provided (project # RA17/002/A). This study was partially supported by the College of Medicine, Research Centre, Deanship of Scientific Research,
458 459 460 461 462 463 464	Institutional Review Bo	The study was conducted in accordance with the Declaration of Helsinki, and was approved by King Abdullah International Medical Research Centre (KAIMRC), National Guard Health Affairs, Saudi Arabia, although no research funding was provided (project # RA17/002/A). This study was partially supported by the College of Medicine, Research Centre, Deanship of Scientific Research, King Saud University, Riyadh, Saudi Arabia. All authors have read and have consented to the acknowledgment.
458 459 460 461 462 463 464 465		The study was conducted in accordance with the Declaration of Helsinki, and was approved by King Abdullah International Medical Research Centre (KAIMRC), National Guard Health Affairs, Saudi Arabia, although no research funding was provided (project # RA17/002/A). This study was partially supported by the College of Medicine, Research Centre, Deanship of Scientific Research, King Saud University, Riyadh, Saudi Arabia. All authors have read and have consented to the acknowledgment.
458 459 460 461 462 463 464 465 466		The study was conducted in accordance with the Declaration of Helsinki, and was approved by King Abdullah International Medical Research Centre (KAIMRC), National Guard Health Affairs, Saudi Arabia, although no research funding was provided (project # RA17/002/A). This study was partially supported by the College of Medicine, Research Centre, Deanship of Scientific Research, King Saud University, Riyadh, Saudi Arabia. All authors have read and have consented to the acknowledgment.
458 459 460 461 462 463 464 465 466 467	Informed Consent State	The study was conducted in accordance with the Declaration of Helsinki, and was approved by King Abdullah International Medical Research Centre (KAIMRC), National Guard Health Affairs, Saudi Arabia, although no research funding was provided (project # RA17/002/A). This study was partially supported by the College of Medicine, Research Centre, Deanship of Scientific Research, King Saud University, Riyadh, Saudi Arabia. All authors have read and have consented to the acknowledgment.
458 459 460 461 462 463 464 465 466 467 468 469		The study was conducted in accordance with the Declaration of Helsinki, and was approved by King Abdullah International Medical Research Centre (KAIMRC), National Guard Health Affairs, Saudi Arabia, although no research funding was provided (project # RA17/002/A). This study was partially supported by the College of Medicine, Research Centre, Deanship of Scientific Research, King Saud University, Riyadh, Saudi Arabia. All authors have read and have consented to the acknowledgment. ement: Informed consent was obtained from all subjects involved in the study
458 459 460 461 462 463 464 465 466 465 466 467 468 469 470	Informed Consent State	The study was conducted in accordance with the Declaration of Helsinki, and was approved by King Abdullah International Medical Research Centre (KAIMRC), National Guard Health Affairs, Saudi Arabia, although no research funding was provided (project # RA17/002/A). This study was partially supported by the College of Medicine, Research Centre, Deanship of Scientific Research, King Saud University, Riyadh, Saudi Arabia. All authors have read and have consented to the acknowledgment. ement: Informed consent was obtained from all subjects involved in the study
458 459 460 461 462 463 464 465 466 467 468 469 470 471	Informed Consent State	The study was conducted in accordance with the Declaration of Helsinki, and was approved by King Abdullah International Medical Research Centre (KAIMRC), National Guard Health Affairs, Saudi Arabia, although no research funding was provided (project # RA17/002/A). This study was partially supported by the College of Medicine, Research Centre, Deanship of Scientific Research, King Saud University, Riyadh, Saudi Arabia. All authors have read and have consented to the acknowledgment. ement: Informed consent was obtained from all subjects involved in the study ment: Data generated from next-generation sequencing have been submitted to NCBI and can be accessed at https://www.ncbi.nlm.nih.gov/sra/PRINA734750 (SRA accession number PRJNA734750),
458 459 460 461 462 463 464 465 466 465 466 467 468 469 470	Informed Consent State	The study was conducted in accordance with the Declaration of Helsinki, and was approved by King Abdullah International Medical Research Centre (KAIMRC), National Guard Health Affairs, Saudi Arabia, although no research funding was provided (project # RA17/002/A). This study was partially supported by the College of Medicine, Research Centre, Deanship of Scientific Research, King Saud University, Riyadh, Saudi Arabia. All authors have read and have consented to the acknowledgment. ement: Informed consent was obtained from all subjects involved in the study
458 459 460 461 462 463 464 465 466 467 468 469 470 471	Informed Consent State	The study was conducted in accordance with the Declaration of Helsinki, and was approved by King Abdullah International Medical Research Centre (KAIMRC), National Guard Health Affairs, Saudi Arabia, although no research funding was provided (project # RA17/002/A). This study was partially supported by the College of Medicine, Research Centre, Deanship of Scientific Research, King Saud University, Riyadh, Saudi Arabia. All authors have read and have consented to the acknowledgment. ement: Informed consent was obtained from all subjects involved in the study ment: Data generated from next-generation sequencing have been submitted to NCBI and can be accessed at https://www.ncbi.nlm.nih.gov/sra/PRINA734750 (SRA accession number PRJNA734750),
458 459 460 461 462 463 464 465 466 467 468 469 470 471 472	Informed Consent State Data Availability Stater	The study was conducted in accordance with the Declaration of Helsinki, and was approved by King Abdullah International Medical Research Centre (KAIMRC), National Guard Health Affairs, Saudi Arabia, although no research funding was provided (project # RA17/002/A). This study was partially supported by the College of Medicine, Research Centre, Deanship of Scientific Research, King Saud University, Riyadh, Saudi Arabia. All authors have read and have consented to the acknowledgment. ement: Informed consent was obtained from all subjects involved in the study ment: Data generated from next-generation sequencing have been submitted to NCBI and can be accessed at https://www.ncbi.nlm.nih.gov/sra/PRINA734750 (SRA accession number PRJNA734750),
458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473	Informed Consent State Data Availability Stater	The study was conducted in accordance with the Declaration of Helsinki, and was approved by King Abdullah International Medical Research Centre (KAIMRC), National Guard Health Affairs, Saudi Arabia, although no research funding was provided (project # RA17/002/A). This study was partially supported by the College of Medicine, Research Centre, Deanship of Scientific Research, King Saud University, Riyadh, Saudi Arabia. All authors have read and have consented to the acknowledgment. ement: Informed consent was obtained from all subjects involved in the study ment: Data generated from next-generation sequencing have been submitted to NCBI and can be accessed at https://www.ncbi.nlm.nih.gov/sra/PRINA734750 (SRA accession number PRJNA734750), accessed on 18 Oct 2023.
458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474	Informed Consent State Data Availability Stater	The study was conducted in accordance with the Declaration of Helsinki, and was approved by King Abdullah International Medical Research Centre (KAIMRC), National Guard Health Affairs, Saudi Arabia, although no research funding was provided (project # RA17/002/A). This study was partially supported by the College of Medicine, Research Centre, Deanship of Scientific Research, King Saud University, Riyadh, Saudi Arabia. All authors have read and have consented to the acknowledgment. ement: Informed consent was obtained from all subjects involved in the study ment: Data generated from next-generation sequencing have been submitted to NCBI and can be accessed at https://www.ncbi.nlm.nih.gov/sra/PRINA734750 (SRA accession number PRJNA734750), accessed on 18 Oct 2023.
458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474	Informed Consent State Data Availability Stater	The study was conducted in accordance with the Declaration of Helsinki, and was approved by King Abdullah International Medical Research Centre (KAIMRC), National Guard Health Affairs, Saudi Arabia, although no research funding was provided (project # RA17/002/A). This study was partially supported by the College of Medicine, Research Centre, Deanship of Scientific Research, King Saud University, Riyadh, Saudi Arabia. All authors have read and have consented to the ac- knowledgment. Ement: Informed consent was obtained from all subjects involved in the study ment: Data generated from next-generation sequencing have been submitted to NCBI and can be ac- cessed at <u>https://www.ncbi.nlm.nih.gov/sra/PRINA734750</u> (SRA accession number PRJNA734750), accessed on 18 Oct 2023. The study was approved by King Abdullah International Medical Research Centre (KAIMRC), National Guard Health Affairs, Saudi Arabia, although no research funding was provided (project # RA17/002/A). This study was partially supported by the College of Medicine, Research Centre,
458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476	Informed Consent State Data Availability Stater	The study was conducted in accordance with the Declaration of Helsinki, and was approved by King Abdullah International Medical Research Centre (KAIMRC), National Guard Health Affairs, Saudi Arabia, although no research funding was provided (project # RA17/002/A). This study was partially supported by the College of Medicine, Research Centre, Deanship of Scientific Research, King Saud University, Riyadh, Saudi Arabia. All authors have read and have consented to the acknowledgment. Ement: Informed consent was obtained from all subjects involved in the study ment: Data generated from next-generation sequencing have been submitted to NCBI and can be accessed at https://www.ncbi.nlm.nih.gov/sra/PRINA734750 (SRA accession number PRJNA734750), accessed on 18 Oct 2023. The study was approved by King Abdullah International Medical Research Centre (KAIMRC), National Guard Health Affairs, Saudi Arabia, although no research funding was provided (project "study").
458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477	Informed Consent State Data Availability Stater	The study was conducted in accordance with the Declaration of Helsinki, and was approved by King Abdullah International Medical Research Centre (KAIMRC), National Guard Health Affairs, Saudi Arabia, although no research funding was provided (project # RA17/002/A). This study was partially supported by the College of Medicine, Research Centre, Deanship of Scientific Research, King Saud University, Riyadh, Saudi Arabia. All authors have read and have consented to the ac- knowledgment. ement: Informed consent was obtained from all subjects involved in the study nent: Data generated from next-generation sequencing have been submitted to NCBI and can be ac- cessed at <u>https://www.ncbi.nlm.nih.gov/sra/PRINA734750</u> (SRA accession number PRJNA734750), accessed on 18 Oct 2023. The study was approved by King Abdullah International Medical Research Centre (KAIMRC), National Guard Health Affairs, Saudi Arabia, although no research funding was provided (project # RA17/002/A). This study was partially supported by the College of Medicine, Research Centre, Deanship of Scientific Research, King Saud University, Riyadh, Saudi Arabia. All authors have read and have consented to the acknowledgment. This project was financed by the National Plan
458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478	Informed Consent State Data Availability Stater	The study was conducted in accordance with the Declaration of Helsinki, and was approved by King Abdullah International Medical Research Centre (KAIMRC), National Guard Health Affairs, Saudi Arabia, although no research funding was provided (project # RA17/002/A). This study was partially supported by the College of Medicine, Research Centre, Deanship of Scientific Research, King Saud University, Riyadh, Saudi Arabia. All authors have read and have consented to the ac- knowledgment. ement: Informed consent was obtained from all subjects involved in the study

481	Conflic	s of Interest:
482		The authors declare no financial or other conflicts of interest.
483		
484	Referen	nces
485	Referen	ces
486		
487	1.	Shah NP, Bhatia R, Altman JK, Amaya M, Begna KH, Berman E, Chan O, Clements J, Collins RH, Curtin PT, DeAngelo
488		DJ, Drazer M, Maness L, Metheny L, Mohan S, Moore JO, Oehler V, Pratz K, Pusic I, Rose MG, Shomali W, Smith BD,
489		Styler M, Talpaz M, Tanaka TN, Tantravahi S, Thompson J, Tsai S, Vaughn J, Welborn J, Yang DT, Sundar H, Gregory K.
490		Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw.
491		2024 Feb;22(1):43-69. doi: 10.6004/jnccn.2024.0007. PMID: 38394770.
492	2.	Rea D, Fodil S, Lengline E, Raffoux E, Cayuela JM. Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid
493		Leukemia: Strategies to Optimize Success and New Directions. Curr Hematol Malig Rep. 2024 Feb 23. doi:
494		10.1007/s11899-024-00728-9. Epub ahead of print. PMID: 38393431.
495	3.	Faria C, Tzankov A. Progression in Myeloid Neoplasms: Beyond the Myeloblast. Pathobiology. 2024;91(1):55-75. doi:
496		10.1159/000530940. Epub 2023 May 11. PMID: 37232015; PMCID: PMC10857805.
497	4.	Zhang R, Hao J, Yu H, Wang ZJ, Lan F, Peng Y, Qiu Y. circ_SIRT1 upregulates ATG12 to facilitate Imatinib resistance in
498		CML through interacting with EIF4A3. Gene. 2024 Jan 30;893:147917. doi: 10.1016/j.gene.2023.147917. Epub 2023 Oct
499		20. PMID: 378666664.
500	5.	Ortí G, Gras L, Koster L, Kulagin A, Byrne J, Apperley JF, Halaburda K, Blau IW, Clark A, Kröger N, Griskevicius L,
501		Carlson K, Collin M, Bloor A, Raiola AM, Blaise D, Aljurf M, López-Corral L, Sakellari I, Beguin Y, Wrobel T, de Rosa
502		L, de Lavallade H, Hayden PJ, McLornan D, Chalandon Y, Yakoub-Agha I. Graft-versus-Host Disease Prophylaxis with
503		Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic
504		Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malig-
505		nancies Working Party of the EBMT (CMWP-EBMT). Transplant Cell Ther. 2024 Jan;30(1):93.e1-93.e12. doi:
506		10.1016/j.jtct.2023.09.019. Epub 2023 Sep 30. PMID: 37783337.
507	6.	Chimge NO, Chen MH, Nguyen C, Zhao Y, Wu X, Gonzalez PG, Ogana H, Hurwitz S, Teo JL, Chen X, Du J, Jin V, Kim
508		YM, Ono M, Argüello RJ, Kahn M. A Deeply Quiescent Subset of CML LSC depend on FAO yet Avoid Deleterious ROS
509		by Suppressing Mitochondrial Complex I. Curr Mol Pharmacol. 2024;17(1):e060923220758. doi:
510		10.2174/1874467217666230906092236. PMID: 37691195.
511	7.	Elmakaty I, Saglio G, Al-Khabori M, Elsayed A, Elsayed B, Elmarasi M, Elsabagh AA, Alshurafa A, Ali E, Yassin M. The
512		Contemporary Role of Hematopoietic Stem Cell Transplantation in the Management of Chronic Myeloid Leukemia: Is It
513		the Same in All Settings? Cancers (Basel). 2024 Feb 12;16(4):754. doi: 10.3390/cancers16040754. PMID: 38398145;
514		PMCID: PMC10886670.
515	8.	Wang G, Wang F, Huang Q, Li Y, Liu Y, Wang Y. Understanding Transcription Factor Regulation by Integrating Gene
516		Expression and DNase I Hypersensitive Sites. Biomed Res Int. 2015;2015:757530. doi:10.1155/2015/757530
517	9.	Bushweller JH. Targeting transcription factors in cancer - from undruggable to reality. Nat Rev Cancer.
518		2019;19(11):611-624. doi:10.1038/s41568-019-0196-7
519	10.	Iqbal Z, Absar M, Akhtar T, Alanazi N, Shammas M, Basit S, Mahmood A. PB1896: WHOLE EXOME SEQUENCING
520		IDENTIFIES A NOVEL TRANSCRIPTION FACTOR ASSOCIATED WITH FATAL DISEASE PROGRESSION IN
521		CHRONIC MYELOID LEUKEMIA. Hemasphere. 2022 Jun 23;6(Suppl):1775-1776. doi:
522		10.1097/01.HS9.0000850436.67961.dd. PMCID: PMC9431465.

523 524 525 526 527	11.	Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Saußele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 Apr;34(4):966-984.
528	12.	Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of
529		concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041-51.
530	13.	Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommen-
531		dations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872-84.
532	14.	Cagnetta A, Garuti A, Marani C, Cea M, Miglino M, Rocco I, Palermo C, Fugazza G, Cirmena G, Colombo N, Grasso R,
533		Nencioni A, Gobbi M, Patrone F. Evaluating treatment response of chronic myeloid leukemia: emerging science and
534		technology. Curr Cancer Drug Targets. 2013 Sep;13(7):779-90. doi: 10.2174/15680096113139990084. PMID: 23906053.
535 536	15.	Cross NC, White HE, Müller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic my- eloid leukemia. Leukemia. 2012 Oct;26(10):2172-5. doi: 10.1038/leu.2012.104. Epub 2012 Apr 16. PMID: 22504141.
537	16.	Mahon FX, Etienne G. Deep molecular response in chronic myeloid leukemia: the new goal of therapy? Clin Cancer Res.
538		2014 Jan 15;20(2):310-22. doi: 10.1158/1078-0432.CCR-13-1988. Epub 2013 Oct 28. PMID: 24166905.
539	17.	Driscoll JJ, Rixe O. Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer
540		clinical trials. Cancer J. 2009 Sep-Oct;15(5):401-5. doi: 10.1097/PPO.0b013e3181bdc2e0. PMID: 19826360.
541	18.	Goel MK, Khanna P, Kishore J. Understanding survival analysis: Kaplan-Meier estimate. Int J Ayurveda Res. 2010
542		Oct;1(4):274-8. doi: 10.4103/0974-7788.76794. PMID: 21455458; PMCID: PMC3059453.
543	19.	Thanarajasingam G, Minasian LM, Baron F, Cavalli F, De Claro RA, Dueck AC, et al. Beyond maximum grade: mod-
544		ernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol.
545		2018;5:e563–e598.
546	20.	Goodyear MD, Krleza-Jeric K, Lemmens T. The Declaration of Helsinki. BMJ. 2007 Sep 29;335(7621):624-5. doi: 10.1126/hmi.20220.010000.PE_PMUD: 17001471; PMC1005406
547	21	10.1136/bmj.39339.610000.BE. PMID: 17901471; PMCID: PMC1995496.
548	21.	Ip SC, Lin SW, Lai KM. An evaluation of the performance of five extraction methods: Chelex® 100, QIAamp® DNA Blood Mini Kit, QIAamp® DNA Investigator Kit, QIAsymphony® DNA Investigator® Kit and DNA IQ [™] . Sci Justice.
549		
550		2015 May;55(3):200-8. doi: 10.1016/j.scijus.2015.01.005. Epub 2015 Jan 28. PMID: 25934373.
551	22.	AlAsiri, S., Basit, S., Wood-Trageser, M., Yatsenko, S. A., Jeffries, E. P., Surti, U., & Haque, M. FU. (2015). Exome
552		sequencing reveals MCM8 mutation underlies ovarian failure and chromosomal instability. *Journal of Clinical Investi-
553		gation*, 125(1), 258-262.
554	23.	Gnirke, A., Melnikov, A., Maguire, J., Rogov, P., LeProust, E. M., Brockman, W., & Nusbaum, C. (2009). Solution
555		hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. *Nature Biotechnology*,
556		27(2), 182-189. doi: 10.1038/nbt.1523.

- 24. Retterer K, Juusola J, Cho MT, Vitazka P, Millan F, Gibellini F, Vertino-Bell A, Smaoui N, Neidich J, Monaghan KG,
 McKnight D, Bai R, Suchy S, Friedman B, Tahiliani J, Pineda-Alvarez D, Richard G, Brandt T, Haverfield E, Chung WK,
 Bale S. Clinical application of whole-exome sequencing across clinical indications. Genet Med. 2016 Jul;18(7):696-704.
 doi: 10.1038/gim.2015.148. Epub 2015 Dec 3. PMID: 26633542.
- 25. Carson AR, Smith EN, Matsui H, Brækkan SK, Jepsen K, Hansen JB, Frazer KA. Effective filtering strategies to improve
 data quality from population-based whole exome sequencing studies. BMC Bioinformatics. 2014 May 2;15:125. doi:
 10.1186/1471-2105-15-125. PMID: 24884706; PMCID: PMC4098776.
- Branford, S.; Wang, P.; Yeung, D.T.; Thomson, D.; Purins, A.; Wadham, C.; Shahrin, N.H.; Marum, J.E.; Nataren, N.;
 Parker, W.T.; et al. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with
 high-risk disease. Blood 2018, 132, 948–961.
- 27. Xu, J.; Wu, M.; Sun, Y.; Zhao, H.; Wang, Y.; Gao, J. Identifying Dysregulated lncRNA-Associated ceRNA Network
 Biomarkers in CML Based on Dynamical Network Biomarkers. BioMed Res. Int. 2020, 2020, 5189549.
- Tsiatis AC, Norris-Kirby A, Rich RG, Hafez MJ, Gocke CD, Eshleman JR, Murphy KM. Comparison of Sanger se quencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn. 2010 Jul;12(4):425-32. doi: 10.2353/jmoldx.2010.090188. Epub 2010 Apr 29. PMID: 20431034;
 PMCID: PMC2893626.
- 29. Beck TF, Mullikin JC; NISC Comparative Sequencing Program, Biesecker LG. Systematic Evaluation of Sanger Validation of Next-Generation Sequencing Variants. Clin Chem. 2016 Apr;62(4):647-54. doi: 10.1373/clinchem.2015.249623.
 Epub 2016 Feb 4. PMID: 26847218; PMCID: PMC4878677.
- 30. Diaz-Horta O, Duman D, Foster J 2nd, Sırmacı A, Gonzalez M, Mahdieh N, Fotouhi N, Bonyadi M, Cengiz FB, Menendez
 I, Ulloa RH, Edwards YJ, Züchner S, Blanton S, Tekin M. Whole-exome sequencing efficiently detects rare mutations in
 autosomal recessive nonsyndromic hearing loss. PLoS One. 2012;7(11):e50628. doi: 10.1371/journal.pone.0050628. Epub
 2012 Nov 30. PMID: 23226338; PMCID: PMC3511533.
- 31. R Core Team (2012). R: A language and environment for statistical computing. R Foundation for Statistical Computing,
 Vienna, Austria. ISBN 3-900051-07-0, URL <u>http://www.R-project.org/</u>
- 32. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, Tso CY, Braun TJ, Clarkson BD, Cervantes F, et al.
 Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood. 1984 Apr;63(4):789-99. PMID: 6584184.
- 33. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, Alimena G, Steegmann JL, Ansari H.
 A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing
 Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998 Jun 3;90(11):850-8. doi:
 10.1093/jnci/90.11.850. PMID: 9625174.
- 34. Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, Guilhot F, Porkka K, Ossenkoppele G, Lindoerfer D,
 Simonsson B, Pfirrmann M, Hehlmann R. Predicting complete cytogenetic response and subsequent progression-free
 survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011 Jul 21;118(3):686-92. doi:
 10.1182/blood-2010-12-319038. Epub 2011 May 2. PMID: 21536864.
- 592 35. Kuntegowdanahalli LC, Kanakasetty GB, Thanky AH, Dasappa L, Jacob LA, Mallekavu SB, Lakkavalli RK, Kadabur LN,
 593 Haleshappa RA. Prognostic and predictive implications of Sokal, Euro and EUTOS scores in chronic myeloid leukaemia in
 594 the imatinib era-experience from a tertiary oncology centre in Southern India. Ecancermedicalscience. 2016 Oct 6;10:679.
 595 doi: 10.3332/ecancer.2016.679. PMID: 27899952; PMCID: PMC5102687.
- 36. Paver EC, Morey AL. Biomarkers and biomarker validation: a pathologist's guide to getting it right. Pathology. 2024
 Mar;56(2):147-157. doi: 10.1016/j.pathol.2023.11.002. Epub 2023 Dec 12. PMID: 38195376.
- 598 37. Knoll K, O'Connor M, Chouchane A, Haller B, Schaarschmidt C, Bock M, Förschner L, Fröhlich R, Kottmaier M, Bourier
 599 F, Reents T, Hessling G, Deisenhofer I, Kolb C, Lennerz C. A prospective case-control validation of procalcitonin as a

biomarker diagnosing pacemaker and implantable cardioverter-defibrillator pocket infection. Kardiol Pol.
 2022;80(7-8):782-791. doi: 10.33963/KP.a2022.0124. Epub 2022 May 6. PMID: 35521718.

- 38. Qiao XR, Zheng T, Xie Y, Yao X, Yuan Z, Wu Y, Zhou D, Chen T. MiR-146a rs2910164 (G/C) polymorphism is associated with the development and prognosis of acute coronary syndromes: an observational study including case control and validation cohort. J Transl Med. 2023 May 15;21(1):325. doi: 10.1186/s12967-023-04140-4. PMID: 37189131; PMCID: PMC10186648.
- Bulfoni M, Sozio E, Marcon B, De Martino M, Cesselli D, De Carlo C, Martinella R, Migotti A, Vania E, Zanus-Fortes A,
 De Piero J, Nencioni E, Tascini C, Isola M, Curcio F. Validation of a Saliva-Based Test for the Molecular Diagnosis of
 SARS-CoV-2 Infection. Dis Markers. 2022 Jan 7;2022:6478434. doi: 10.1155/2022/6478434. PMID: 35035611; PMCID:
 PMC8759915.
- 40. Fernández-Sanlés A, Sayols-Baixeras S, Subirana I, Sentí M, Pérez-Fernández S, de Castro Moura M, Esteller M, Marrugat
 J, Elosua R. DNA methylation biomarkers of myocardial infarction and cardiovascular disease. Clin Epigenetics. 2021 Apr
 21;13(1):86. doi: 10.1186/s13148-021-01078-6. PMID: 33883000; PMCID: PMC8061080.
- 41. Peters TJ, Meyer B, Ryan L, Achinger-Kawecka J, Song J, Campbell EM, Qu W, Nair S, Loi-Luu P, Stricker P, Lim E,
 Stirzaker C, Clark SJ, Pidsley R. Characterisation and reproducibility of the HumanMethylationEPIC v2.0 BeadChip for
 DNA methylation profiling. BMC Genomics. 2024 Mar 6;25(1):251. doi: 10.1186/s12864-024-10027-5. PMID:
 38448820; PMCID: PMC10916044.
- 42. Philibert R, Dogan TK, Knight S, Ahmad F, Lau S, Miles G, Knowlton KU, Dogan MV. Validation of an Integrated Genetic-Epigenetic Test for the Assessment of Coronary Heart Disease. J Am Heart Assoc. 2023 Nov 20;12(22):e030934. doi: 10.1161/JAHA.123.030934. Epub ahead of print. PMID: 37982274; PMCID: PMC10727271.
- 43. Zhan C, Tang T, Wu E, Zhang Y, He M, Wu R, Bi C, Wang J, Zhang Y, Shen B. From multi-omics approaches to personalized medicine in myocardial infarction. Front Cardiovasc Med. 2023 Oct 30;10:1250340. doi:
 10.3389/fcvm.2023.1250340. PMID: 37965091; PMCID: PMC10642346.
- 44. Neagu AN, Whitham D, Bruno P, Morrissiey H, Darie CA, Darie CC. Omics-Based Investigations of Breast Cancer.
 Molecules. 2023 Jun 14;28(12):4768. doi: 10.3390/molecules28124768. PMID: 37375323; PMCID: PMC10302907.
- 45. Neagu AN, Whitham D, Bruno P, Arshad A, Seymour L, Morrissiey H, Hukovic AI, Darie CC. Onco-Breastomics: An
 Eco-Evo-Devo Holistic Approach. Int J Mol Sci. 2024 Jan 28;25(3):1628. doi: 10.3390/ijms25031628. PMID: 38338903;
 PMCID: PMC10855488.
- 46. Abbasi EY, Deng Z, Ali Q, Khan A, Shaikh A, Reshan MSA, Sulaiman A, Alshahrani H. A machine learning and deep
 learning-based integrated multi-omics technique for leukemia prediction. Heliyon. 2024 Feb 1;10(3):e25369. doi:
 10.1016/j.heliyon.2024.e25369. PMID: 38352790; PMCID: PMC10862685.
- 47. Tsagiopoulou M, Gut IG. Machine learning and multi-omics data in chronic lymphocytic leukemia: the future of precision
 medicine? Front Genet. 2024 Jan 12;14:1304661. doi: 10.3389/fgene.2023.1304661. PMID: 38283149; PMCID:
 PMC10811210.
- 48. Miao YR, Liu W, Zhong Z, You Y, Tang Y, Li W, Zhu X, Guo AY. Case Report: Multi-Omics Analysis and CAR-T
 Treatment of a Chronic Myeloid Leukemia Blast Crisis Case 5 Years After the Discontinuation of TKI. Front Oncol. 2021
 Sep 21;11:739871. doi: 10.3389/fonc.2021.739871. PMID: 34621680; PMCID: PMC8490701.
- 49. Srivastava A, Srivastava S. Multiomics data identifies RSPO2 as a prognostic biomarker in human tumors associated with
 pan-cancer. Adv Protein Chem Struct Biol. 2024;139:469-499. doi: 10.1016/bs.apcsb.2023.11.011. Epub 2024 Feb 17.
 PMID: 38448143.

640

50. Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A,
 Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Müller MC, Jeromin S, Proetel U,

Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler MC, Hänel M, Ho A, Dengler J,

- Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne CA, Lindemann HW, Waller CF, Pfreundschuh
- M, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R,
- 646 Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek
- 647 W, Eckart MJ, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J.
- Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized
 CML study IV and impact of non-CML determinants. Leukemia. 2017 Nov;31(11):2398-2406. doi: 10.1038/leu.2017.253.
- Epub 2017 Aug 14. PMID: 28804124; PMCID: PMC5668495.
- 51. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A,
 Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM,
 Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ; IRIS Investigators. Imatinib compared with
 interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003 Mar
 13;348(11):994-1004. doi: 10.1056/NEJMoa022457. PMID: 12637609.
- Ahmad R, Tripathi AK, Tripathi P, Singh S, Singh R, Singh RK. Malondialdehyde and protein carbonyl as biomarkers for
 oxidative stress and disease progression in patients with chronic myeloid leukemia. In Vivo. 2008 Jul-Aug;22(4):525-8.
 PMID: 18712183.
- 53. Wells JN, Chang NC, McCormick J, Coleman C, Ramos N, Jin B, Feschotte C. Transposable elements drive the evolution
 of metazoan zinc finger genes. Genome Res. 2023 Aug;33(8):1325-1339. doi: 10.1101/gr.277966.123. Epub 2023 Sep 15.
 PMID: 37714714; PMCID: PMC10547256.
- 54. Becker KG, Nagle JW, Canning RD, Biddison WE, Ozato K, Drew PD. Rapid isolation and characterization of 118 novel
 C2H2-type zinc finger cDNAs expressed in human brain. Hum Mol Genet. 1995 Apr;4(4):685-91. doi:
 10.1093/hmg/4.4.685. PMID: 7633419.
- 55. Jen J, Wang YC. Zinc finger proteins in cancer progression. J Biomed Sci. 2016 Jul 13;23(1):53. doi:
 10.1186/s12929-016-0269-9. PMID: 27411336; PMCID: PMC4944467.
- 56. Yang L, Zhang L, Wu Q, Boyd DD. Unbiased screening for transcriptional targets of ZKSCAN3 identifies integrin beta 4
 and vascular endothelial growth factor as downstream targets. J Biol Chem. 2008 Dec 12;283(50):35295-304. doi:
 10.1074/jbc.M806965200. Epub 2008 Oct 21. PMID: 18940803; PMCID: PMC2596387.
- 57. O'Sullivan J, Kothari C, Caron MC, Gagné JP, Jin Z, Nonfoux L, Beneyton A, Coulombe Y, Thomas M, Atalay N, Meng
 KW, Milano L, Jean D, Boisvert FM, Kaufmann SH, Hendzel MJ, Masson JY, Poirier GG. ZNF432 stimulates PARylation
 and inhibits DNA resection to balance PARPi sensitivity and resistance. Nucleic Acids Res. 2023 Oct 12:gkad791. doi:
 10.1093/nar/gkad791. Epub ahead of print. PMID: 37823600.
- 58. Codd V, Nelson CP, Albrecht E, Mangino M, Deelen J, Buxton JL, Hottenga JJ, Fischer K, Esko T, Surakka I, Broer L, 674 675 Nyholt DR, Mateo Leach I, Salo P, Hägg S, Matthews MK, Palmen J, Norata GD, O'Reilly PF, Saleheen D, Amin N, Balmforth AJ, Beekman M, de Boer RA, Böhringer S, Braund PS, Burton PR, de Craen AJ, Denniff M, Dong Y, Douroudis 676 K, Dubinina E, Eriksson JG, Garlaschelli K, Guo D, Hartikainen AL, Henders AK, Houwing-Duistermaat JJ, Kananen L, 677 Karssen LC, Kettunen J, Klopp N, Lagou V, van Leeuwen EM, Madden PA, Mägi R, Magnusson PK, Männistö S, 678 679 McCarthy MI, Medland SE, Mihailov E, Montgomery GW, Oostra BA, Palotie A, Peters A, Pollard H, Pouta A, Prokopenko I, Ripatti S, Salomaa V, Suchiman HE, Valdes AM, Verweij N, Viñuela A, Wang X, Wichmann HE, Widen E, 680 Willemsen G, Wright MJ, Xia K, Xiao X, van Veldhuisen DJ, Catapano AL, Tobin MD, Hall AS, Blakemore AI, van Gilst 681 WH, Zhu H; CARDIoGRAM consortium, Erdmann J, Reilly MP, Kathiresan S, Schunkert H, Talmud PJ, Pedersen NL, 682 Perola M, Ouwehand W, Kaprio J, Martin NG, van Duijn CM, Hovatta I, Gieger C, Metspalu A, Boomsma DI, Jarvelin 683
- 684 MR, Slagboom PE, Thompson JR, Spector TD, van der Harst P, Samani NJ. Identification of seven loci affecting mean

- telomere length and their association with disease. Nat Genet. 2013 Apr;45(4):422-7, 427e1-2. doi: 10.1038/ng.2528.
 PMID: 23535734; PMCID: PMC4006270.
- 59. Munro D, Ghersi D, Singh M. Two critical positions in zinc finger domains are heavily mutated in three human cancer
 types. PLoS Comput Biol. 2018 Jun 28;14(6):e1006290. doi: 10.1371/journal.pcbi.1006290. PMID: 29953437; PMCID:
 PMC6040777.
- 60. Walsh KM, Whitehead TP, de Smith AJ, Smirnov IV, Park M, Endicott AA, Francis SS, Codd V; ENGAGE Consortium
 Telomere Group, Samani NJ, Metayer C, Wiemels JL. Common genetic variants associated with telomere length confer
 risk for neuroblastoma and other childhood cancers. Carcinogenesis. 2016 Jun;37(6):576-582. doi:
 10.1093/carcin/bgw037. Epub 2016 Apr 1. PMID: 27207662; PMCID: PMC4876988.
- 61. Wang H, Yu J, Guo Y, Zhang Z, Liu G, Li J, Zhang X, Jin T, Wang Z. Genetic variants in the ZNF208 gene are associated
 with esophageal cancer in a Chinese Han population. Oncotarget. 2016 Dec 27;7(52):86829-86835. doi:
 10.18632/oncotarget.13468. PMID: 27907911; PMCID: PMC5349957.
- 697 62. Wang S, Wen X, Zhao R, Bai Y. Genetic Variation in the ZNF208 Gene at rs8103163 and rs7248488 Is Associated With
 698 Laryngeal Cancer in the Northwestern Chinese Han Male. Front Genet. 2022 Apr 11;13:813823. doi:
 699 10.3389/fgene.2022.813823. PMID: 35480322; PMCID: PMC9035488.
- 63. Ding Y, Zhou X, Wu C, Li Q, Sun J, Niu H, Lin D, Sun D, Xie P, Wu D, Zhao J, He P. Telomere length, ZNF208 genetic
 variants and risk of chronic obstructive pulmonary disease in the Hainan Li population. J Gene Med. 2018
 Dec;20(12):e3061. doi: 10.1002/jgm.3061. Epub 2018 Nov 28. PMID: 30397981.
- 64. Sun W, Hang D, Han S, Fu S, Ma H, Dong X, Xu Y, Li N, Hu Z. Construction of circRNA-associated ceRNA network
 reveals the regulation of fibroblast proliferation in cervical cancer. Gene. 2022 Nov 30;844:146824. doi:
 10.1016/j.gene.2022.146824. Epub 2022 Aug 19. PMID: 35995117.
- 65. Liu Z, Kruhlak MJ, Thiele CJ. Zinc finger transcription factor CASZ1b is involved in the DNA damage response in live
 cells. Biochem Biophys Res Commun. 2023 Jun 30;663:171-178. doi: 10.1016/j.bbrc.2023.04.085. Epub 2023 Apr 25.
 PMID: 37121127.
- 66. Kang H, Park S, Jo A, Mao X, Kumar M, Park CH, Ahn JY, Lee Y, Choi JY, Lee YS, Dawson VL, Dawson TM, Kam TI,
 Shin JH. PARIS undergoes liquid-liquid phase separation and poly(ADP-ribose)-mediated solidification. EMBO Rep.
 2023 Oct 23:e56166. doi: 10.15252/embr.202256166. Epub ahead of print. PMID: 37870275.
- 712 67. Taka JRH, Sun Y, Goldstone DC. Mapping the interaction between Trim28 and the KRAB domain at the center of Trim28 silencing of endogenous retroviruses. Protein Sci. 2022 Oct;31(10):e4436. doi: 10.1002/pro.4436. PMID: 36173157;
 714 PMCID: PMC9601868.
- 68. Rosspopoff O, Trono D. Take a walk on the KRAB side. Trends Genet. 2023 Nov;39(11):844-857. doi:
 10.1016/j.tig.2023.08.003. Epub 2023 Sep 14. Erratum in: Trends Genet. 2024 Feb;40(2):203-205. PMID: 37716846.
- Rosspopoff O, Trono D. Take a walk on the KRAB side: (Trends in Genetics, 39:11 p:844-857, 2023). Trends Genet. 2024
 Feb;40(2):203-205. doi: 10.1016/j.tig.2023.12.007. Epub 2023 Dec 30. Erratum for: Trends Genet. 2023
 Nov;39(11):844-857. PMID: 38160062.
- 720 70. Chang YJ, Lin S, Kang ZF, Shen BJ, Tsai WH, Chen WC, Lu HP, Su YL, Chou SJ, Lin SY, Lin SW, Huang YJ, Wang HH,
 721 Chang CJ. Acetylation-Mimic Mutation of TRIM28-Lys304 to Gln Attenuates the Interaction with KRAB-Zinc-Finger
 722 Proteins and Affects Gene Expression in Leukemic K562 Cells. Int J Mol Sci. 2023 Jun 6;24(12):9830. doi:
 723 10.3390/ijms24129830. PMID: 37372979; PMCID: PMC10298087.
- 71. Abbasi EY, Deng Z, Ali Q, Khan A, Shaikh A, Reshan MSA, Sulaiman A, Alshahrani H. A machine learning and deep
 learning-based integrated multi-omics technique for leukemia prediction. Heliyon. 2024 Feb 1;10(3):e25369. doi:
 10.1016/j.heliyon.2024.e25369. PMID: 38352790; PMCID: PMC10862685.